Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results
- Citation:
- J Neurooncol vol 92 (2) 165-175
- Year:
- 2009
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10 CA052352, U10 CA037417, U10 CA035269, U10 CA037417-24, CA-52352, U10 CA063848-16, U10 CA035195-24, CA-35195, U10 CA035415-24, U10 CA063849-16, U10 CA035103-24, U10 CA035448, U10 CA063848, U10 CA035269-24, U10 CA035195, U10 CA052352-20, CA-35103, U10 CA025224-24, U10 CA035101, CA-63848, U10 CA035415, U10 CA063849, CA-35415, CA25224, CA-37417, U10 CA035448-24, CA-35269, CA-35448, CA-35101, U10 CA025224, CA-63849, U10 CA035103
- Corr. Author:
- Authors:
- Marta Santisteban Jan C. Buckner Joel M. Reid Wenting Wu Bernd W. Scheithauer Matthew M. Ames Sara J. Felten Daniel A. Nikcevich Martin Wiesenfeld Kurt A. Jaeckle Evanthia Galanis
- Networks:
- Study
- NCCTG-96-72-51
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Enzyme-inducing antiepileptic drugs, Dexamethasone, Irinotecan, Pharmacokinetics, Recurrent gliomas